Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Fingerprint Dive into the research topics of 'Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA'. Together they form a unique fingerprint.